← Back to publications

Economics and Health

Prevention As An Investment: The Case for Preventive Care in Africa

Published 11 October 2026
PDF, 20 pages

Download PDF

South Africa’s consolidated health expenditure is projected at R310 billion in 2026/27. The estimated economic burden of non-communicable diseases averages 4.4% of GDP across the 22 countries for which such estimates are available. Applied to South Africa’s GDP of R7.6 trillion, this implies an annual burden exceeding R300 billion before accounting for HIV, tuberculosis and injuries. To date, South Africa has not produced a comprehensive estimate of the economy-wide return on investment which could arise from prevention. 

The existing evidence is disease-specific: the HIV Investment Case identified two prevention interventions that are cost-saving, while the mental health investment case reports returns broken down by condition. Both analyses are limited to single disease areas. By contrast, none of the six consumption-linked risk factors that account for a large share of the national disease burden have been costed in the same way, and no investment case has consolidated the preventive health agenda into a single fiscal and economic estimate. This gap in analysis persists despite domestic evidence that preventive instruments can be effective: the Health Promotion Levy reduced sugar purchased in taxed beverages by roughly one-third within a year and mandatory sodium limits reduced salt intake by more than one gram per day. 

Prevention offers fiscal and economic returns for South Africa. Currently, however, there is no national estimate framed in terms relevant to the Treasury, nor an institutional mechanism that brings returns accruing to other budgets into allocation decisions.

Read the full paper